Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Laboratory of Neurobiology, Center for Brain & Disease Research, VIB, Leuven, Belgium.
CNS Neurosci Ther. 2023 Jan;29(1):70-77. doi: 10.1111/cns.13960. Epub 2022 Sep 1.
The aim of this study was to investigate whether neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in cerebrospinal fluid (CSF), sampled prior to referral to a neuromuscular reference center (NMRC), shorten the diagnostic delay in patients with amyotrophic lateral sclerosis.
In this retrospective study, patients with ALS were included with (i) determination of neurofilaments (Nfs) before referral to the NMRC (preC-Nfs ALS, n = 58), (ii) determination of Nfs at the NMRC (C-Nfs, n = 54) or (iii) with no determination of Nfs (C-No Nfs, n = 180). Fifty-six disease controls were included.
The preC-Nfs cohort had CSF sampled 2.2 months (range: 0.6-12.0 months) before referral to the NMRC. In this cohort, the diagnostic delay was significantly shorter [median (range): 8.24 (2.37-49.7) months] than in the C-Nfs cases [median (range): 11.4 (2.93-86.5) months; p < 0.05], but not in the C-No Nfs cases. When including the disease progression rate and the presence of a genetic mutation as covariates, the difference ceased to exist (p = 0.14). pNfH and NfL levels in the preC-Nfs cohort were significantly higher than in disease controls (p < 0.0001). Both Nfs showed a similar discriminating performance.
CSF Nfs assessed before the diagnosis of ALS at a NMRC decreased the diagnostic delay in specific cases by 3 months and only when other covariates were not taken into account.
本研究旨在探讨在转诊至神经肌肉参考中心(NMRC)之前采集的脑脊液(CSF)中的神经丝轻链(NfL)和磷酸化神经丝重链(pNfH)是否能缩短肌萎缩侧索硬化症(ALS)患者的诊断延迟。
在这项回顾性研究中,我们纳入了以下患者:(i)在转诊至 NMRC 之前测定神经丝(Nfs)(preC-Nfs ALS 组,n=58),(ii)在 NMRC 测定 Nfs(C-Nfs 组,n=54),或(iii)未测定 Nfs(C-No Nfs 组,n=180)。我们纳入了 56 名疾病对照者。
preC-Nfs 组的 CSF 样本采集时间在转诊至 NMRC 前 2.2 个月(范围:0.6-12.0 个月)。在该队列中,诊断延迟显著缩短[中位数(范围):8.24(2.37-49.7)个月],明显短于 C-Nfs 组[中位数(范围):11.4(2.93-86.5)个月;p<0.05],但与 C-No Nfs 组无差异。当纳入疾病进展率和基因突变存在作为协变量时,这种差异不再存在(p=0.14)。preC-Nfs 组的 pNfH 和 NfL 水平明显高于疾病对照组(p<0.0001)。这两种 Nfs 的鉴别性能相似。
在 NMRC 诊断 ALS 之前评估 CSF Nfs 可将特定病例的诊断延迟缩短 3 个月,但前提是不考虑其他协变量。